Clinical Trial: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma

Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional

Official Title: A Phase II Trial of BIBF1120 in Patients With Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and

Brief Summary: BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.

Detailed Summary:
Sponsor: National Taiwan University Hospital

Current Primary Outcome: Response rate assessed by RECEST version 1.1 [ Time Frame: 2 months ]

To define the response rate of BIBF1120 in patients with advanced FGFR3-mutated,overexpressed,wild type UC and who have failed platinum-based chemotherapy.


Original Primary Outcome: response rate [ Time Frame: 2 months ]

Objective response will be assessed by RECEST version 1.1.


Current Secondary Outcome:

Original Secondary Outcome:

Information By: National Taiwan University Hospital

Dates:
Date Received: October 28, 2014
Date Started: October 2014
Date Completion: March 2016
Last Updated: May 10, 2015
Last Verified: May 2015